Bausch + Lomb Co. (NYSE:BLCO) Position Boosted by Tudor Investment Corp ET AL

Tudor Investment Corp ET AL raised its holdings in shares of Bausch + Lomb Co. (NYSE:BLCO - Free Report) by 133.6% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 263,299 shares of the company's stock after acquiring an additional 150,597 shares during the quarter. Tudor Investment Corp ET AL owned approximately 0.07% of Bausch + Lomb worth $4,755,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other hedge funds have also recently modified their holdings of BLCO. Alberta Investment Management Corp increased its stake in Bausch + Lomb by 36.0% in the 4th quarter. Alberta Investment Management Corp now owns 3,008,193 shares of the company's stock worth $54,328,000 after buying an additional 796,400 shares in the last quarter. Price T Rowe Associates Inc. MD bought a new stake in Bausch + Lomb in the 4th quarter worth approximately $14,122,000. Arrowstreet Capital Limited Partnership raised its stake in Bausch + Lomb by 51.5% during the fourth quarter. Arrowstreet Capital Limited Partnership now owns 1,218,431 shares of the company's stock valued at $21,996,000 after purchasing an additional 414,138 shares in the last quarter. Barclays PLC bought a new position in Bausch + Lomb during the third quarter valued at $5,797,000. Finally, Raymond James Financial Inc. bought a new stake in Bausch + Lomb during the fourth quarter worth approximately $2,844,000. Institutional investors own 11.07% of the company's stock.

Analyst Upgrades and Downgrades

A number of equities analysts recently issued reports on the company. Evercore ISI dropped their price objective on Bausch + Lomb from $19.00 to $15.50 and set an "outperform" rating for the company in a report on Thursday. Royal Bank of Canada reduced their price target on Bausch + Lomb from $18.00 to $17.00 and set an "outperform" rating for the company in a research report on Friday, April 4th. HC Wainwright lowered their target price on shares of Bausch + Lomb from $20.00 to $15.00 and set a "buy" rating for the company in a research note on Friday. Wells Fargo & Company dropped their price target on Bausch + Lomb from $15.00 to $12.00 and set an "equal weight" rating on the stock in a research note on Thursday. Finally, Needham & Company LLC reaffirmed a "hold" rating on shares of Bausch + Lomb in a report on Thursday, April 24th. One investment analyst has rated the stock with a sell rating, seven have issued a hold rating and four have assigned a buy rating to the company's stock. According to data from MarketBeat.com, the company has a consensus rating of "Hold" and a consensus price target of $16.14.

Bausch + Lomb Price Performance

Shares of BLCO traded down $0.13 on Monday, reaching $11.37. The stock had a trading volume of 1,638,654 shares, compared to its average volume of 650,535. The company has a quick ratio of 1.01, a current ratio of 1.60 and a debt-to-equity ratio of 0.72. The firm has a market capitalization of $4.02 billion, a PE ratio of -12.49, a PEG ratio of 0.85 and a beta of 0.58. Bausch + Lomb Co. has a twelve month low of $10.45 and a twelve month high of $21.69. The firm has a 50-day moving average of $13.91 and a 200 day moving average of $16.86.

Bausch + Lomb (NYSE:BLCO - Get Free Report) last issued its quarterly earnings data on Wednesday, April 30th. The company reported ($0.07) earnings per share (EPS) for the quarter, missing the consensus estimate of $0.03 by ($0.10). Bausch + Lomb had a positive return on equity of 3.35% and a negative net margin of 6.62%. The company had revenue of $1.15 billion for the quarter, compared to analyst estimates of $1.15 billion. The company's revenue for the quarter was up 3.5% on a year-over-year basis. During the same quarter in the prior year, the firm earned $0.07 earnings per share. Sell-side analysts expect that Bausch + Lomb Co. will post 0.74 EPS for the current year.

About Bausch + Lomb

Bausch + Lomb Corporation operates as an eye health company in the United States, Puerto Rico, China, France, Japan, Germany, the United Kingdom, Canada, Russia, Spain, Italy, Mexico, Poland, South Korea, and internationally. It operates in three segments: Vision Care, Pharmaceuticals, and Surgical. The Vision Care segment provides contact lens that covers the spectrum of wearing modalities, including daily disposable and frequently replaced contact lenses; and contact lens care products comprising over-the-counter eye drops, eye vitamins, and mineral supplements that address various conditions, such as eye allergies, conjunctivitis, dry eye, and redness relief.